Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study-Reference-Cited by-同舟云学术

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Published:2021-01 Issue:1 Volume:22 Page:142-154
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Laubach Jacob P,Schjesvold Fredrik,Mariz Mário,Dimopoulos Meletios A,Lech-Maranda Ewa,Spicka Ivan,Hungria Vania T M,Shelekhova Tatiana,Abdo Andre,Jacobasch Lutz,Polprasert Chantana,Hájek Roman,Illés Árpád,Wróbel Tomasz,Sureda Anna,Beksac Meral,Gonçalves Iara Z,Bladé Joan,Rajkumar S Vincent,Chari Ajai,Lonial Sagar,Spencer Andrew,Maison-Blanche Pierre,Moreau Philippe,San-Miguel Jesus F,Richardson Paul G

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

2. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group;Laubach;Leukemia,2016

3. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

4. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma;Richardson;Blood,2013

5. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment;Richardson;Blood,2016

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals;Life Sciences;2024-06

2. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities;Signal Transduction and Targeted Therapy;2024-05-22

3. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23

4. Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations;Acta Pharmacologica Sinica;2024-02-21

5. Amphiphilic Poly(2-oxazoline)s with Glycine-Containing Hydrophobic Blocks Tailored for Panobinostat- and Imatinib-Loaded Micelles;Biomacromolecules;2023-11-21